(Q36790658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

The threat of avian influenza A (H5N1). Part III: Antiviral therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

3

Hans W Doerr

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1

Jindrich Cinatl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

1 reference

12 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

Medical Microbiology and Immunology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

203-212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Vaccines and antiviral drugs in pandemic preparedness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Human disease from influenza A (H5N1), Thailand, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Suppression by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Oral ribavirin treatment of influenza A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-007-0048-Z

Anti-inflammatory properties of Type I interferons

21 January 2018

1 reference

12 December 2020

Prevention and treatment of influenza

1 reference

12 December 2020

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

1 reference

12 December 2020

The specific inhibition of influenza A virus maturation by amantadine: an electron microscopic examination

1 reference

12 December 2020

Re-emergence of fatal human influenza A subtype H5N1 disease

1 reference

12 December 2020

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.

1 reference

12 December 2020

Lethal H5N1 influenza viruses escape host anti-viral cytokine responses

1 reference

12 December 2020

Roles of neuraminidase in the initial stage of influenza virus infection

1 reference

12 December 2020

Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice

1 reference

12 December 2020

WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.

1 reference

12 December 2020

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

12 December 2020

Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.

1 reference

12 December 2020

Oseltamivir resistance during treatment of influenza A (H5N1) infection

1 reference

12 December 2020

Avian influenza A (H5N1) infection in humans

1 reference

12 December 2020

Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma

1 reference

12 December 2020

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

12 December 2020

Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.

1 reference

12 December 2020

Avian influenza A (H5N1) in 10 patients in Vietnam

1 reference

12 December 2020

The molecular basis of the specific anti-influenza action of amantadine

1 reference

12 December 2020

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

1 reference

12 December 2020

Antiviral activity of alpha-methyl-1-adamantanemethylamine hydrochloride

1 reference

12 December 2020

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

12 December 2020

Anti-Influenza Viral Activity of Aspirin in Cell Culture

1 reference

12 December 2020

Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs.

1 reference

12 December 2020

Pleiotropic mechanisms of ribavirin antiviral activities

1 reference

12 December 2020

Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial

1 reference

12 December 2020

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

1 reference

12 December 2020

Prevention of Russian Influenza by Amantadine

1 reference

12 December 2020

Characterization of temperature sensitive influenza virus mutants defective in neuraminidase

1 reference

12 December 2020

H5N1 influenza--continuing evolution and spread

1 reference

12 December 2020

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus

1 reference

12 December 2020

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

1 reference

12 December 2020

Oral oseltamivir treatment of influenza in children.

1 reference

12 December 2020

Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine

1 reference

12 December 2020

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

1 reference

12 December 2020

From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors

1 reference

12 December 2020

Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient

1 reference

12 December 2020

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

1 reference

12 December 2020

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

1 reference

12 December 2020

Neuraminidase inhibitors for influenza

1 reference

12 December 2020

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

12 December 2020

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations

1 reference

12 December 2020

The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology.

1 reference

12 December 2020

Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions

1 reference

12 December 2020

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

1 reference

12 December 2020

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

1 reference

12 December 2020

The role of antivirals in the control of influenza.

1 reference

12 December 2020

Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells

1 reference

12 December 2020

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

12 December 2020

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

1 reference

12 December 2020

Avian influenza. With change in the seasons, bird flu returns

1 reference

12 December 2020

Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2

1 reference

12 December 2020

Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action

1 reference

12 December 2020

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

1 reference

12 December 2020

Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection.

1 reference

12 December 2020

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

1 reference

12 December 2020

Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.

1 reference

12 December 2020

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

12 December 2020

Treating HCV with ribavirin analogues and ribavirin-like molecules

1 reference

12 December 2020

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

1 reference

12 December 2020

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

12 December 2020

Antivirals for influenza: historical perspectives and lessons learned

1 reference

12 December 2020

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

1 reference

12 December 2020

The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants.

1 reference

12 December 2020

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

12 December 2020

Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors

1 reference

12 December 2020

Antivirals for the treatment and prevention of epidemic and pandemic influenza

1 reference

12 December 2020

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

1 reference

12 December 2020

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

1 reference

12 December 2020

The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells.

1 reference

12 December 2020

Overview of virus-induced airway disease.

1 reference

12 December 2020

High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza

1 reference

12 December 2020

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

1 reference

12 December 2020

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza

1 reference

12 December 2020

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

1 reference

12 December 2020

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

1 reference

12 December 2020

Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity

1 reference

12 December 2020

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

1 reference

12 December 2020

Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus

1 reference

12 December 2020

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

1 reference

12 December 2020

H5N1 Virus Attachment to Lower Respiratory Tract

1 reference

12 December 2020

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

1 reference

12 December 2020

The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses

1 reference

12 December 2020

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

1 reference

12 December 2020

Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene

1 reference

12 December 2020

In vitro and in vivo influenza virus-inhibitory effects of viramidine

1 reference

12 December 2020

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

1 reference

12 December 2020

10.1007/S00430-007-0048-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17431677%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference